Archives of Neuroscience

Published by: Kowsar

Ocular and Visual Manifestation of the Alzheimer’s Disease: A Literature Review, Part I: Animal Models and Human Pathology

Francesco Raudino 1 , *
Author Information
1 Department of Neurology Valduce Hospital, Como, Italy
Article information
  • Archives of Neuroscience: October 2018, 5 (4); e74225
  • Published Online: August 20, 2018
  • Article Type: Review Article
  • Received: May 2, 2018
  • Accepted: August 8, 2018
  • DOI: 10.5812/ans.74225

To Cite: Raudino F. Ocular and Visual Manifestation of the Alzheimer’s Disease: A Literature Review, Part I: Animal Models and Human Pathology, Arch Neurosci. 2018 ; 5(4):e74225. doi: 10.5812/ans.74225.

Abstract
Copyright © 2018, Archives of Neuroscience. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Context
2. Evidence Acquisition
3. Results
4. Discussion
References
  • 1. Raudino F. Non-cognitive symptoms and related conditions in the Alzheimer's disease: a literature review. Neurol Sci. 2013;34(8):1275-82. doi: 10.1007/s10072-013-1424-7. [PubMed: 23543394].
  • 2. Bowen M, Edgar DF, Hancock B, Haque S, Shah R, Buchanan S. The prevalence of visual impairment in people with dementia (the PrOVIDe study): a cross-sectional study of people aged 60-89 years with dementia and qualitative exploration of individual, carer and professional perspectives. Southampton (UK): NIHR Journals Library; 2016.
  • 3. Kaeser PF, Ghika J, Borruat FX. Visual signs and symptoms in patients with the visual variant of Alzheimer disease. BMC Ophthalmol. 2015;15:65. doi: 10.1186/s12886-015-0060-9. [PubMed: 26122482]. [PubMed Central: PMC4485862].
  • 4. Ning A, Cui J, To E, Ashe KH, Matsubara J. Amyloid-beta deposits lead to retinal degeneration in a mouse model of Alzheimer disease. Invest Ophthalmol Vis Sci. 2008;49(11):5136-43. doi: 10.1167/iovs.08-1849. [PubMed: 18566467]. [PubMed Central: PMC3947384].
  • 5. Perez SE, Lumayag S, Kovacs B, Mufson EJ, Xu S. Beta-amyloid deposition and functional impairment in the retina of the APPswe/PS1DeltaE9 transgenic mouse model of Alzheimer's disease. Invest Ophthalmol Vis Sci. 2009;50(2):793-800. doi: 10.1167/iovs.08-2384. [PubMed: 18791173]. [PubMed Central: PMC3697019].
  • 6. Gupta VK, Chitranshi N, Gupta VB, Golzan M, Dheer Y, Wall RV, et al. Amyloid beta accumulation and inner retinal degenerative changes in Alzheimer's disease transgenic mouse. Neurosci Lett. 2016;623:52-6. doi: 10.1016/j.neulet.2016.04.059. [PubMed: 27133194].
  • 7. Dutescu RM, Li QX, Crowston J, Masters CL, Baird PN, Culvenor JG. Amyloid precursor protein processing and retinal pathology in mouse models of Alzheimer's disease. Graefes Arch Clin Exp Ophthalmol. 2009;247(9):1213-21. doi: 10.1007/s00417-009-1060-3. [PubMed: 19271231].
  • 8. Liu B, Rasool S, Yang Z, Glabe CG, Schreiber SS, Ge J, et al. Amyloid-peptide vaccinations reduce {beta}-amyloid plaques but exacerbate vascular deposition and inflammation in the retina of Alzheimer's transgenic mice. Am J Pathol. 2009;175(5):2099-110. doi: 10.2353/ajpath.2009.090159. [PubMed: 19834067]. [PubMed Central: PMC2774073].
  • 9. Koronyo-Hamaoui M, Koronyo Y, Ljubimov AV, Miller CA, Ko MHK, Black KL. Identification of amyloid plaques in retinas from alzheimer's patients and noninvasive in vivo optical imaging of retinal plaques in a mouse model. Neuroimage. 2011;54S1. S204–S17.
  • 10. Yang Y, Shiao C, Hemingway JF, Jorstad NL, Shalloway BR, Chang R, et al. Suppressed retinal degeneration in aged wild type and APPswe/PS1DeltaE9 mice by bone marrow transplantation. PLoS One. 2013;8(6). e64246. doi: 10.1371/journal.pone.0064246. [PubMed: 23750207]. [PubMed Central: PMC3672108].
  • 11. Gasparini L, Crowther RA, Martin KR, Berg N, Coleman M, Goedert M. Tau inclusions in retinal ganglion cells of human P301S tau transgenic mice: Effects on axonal viability. Neurobiol Aging. 2011;32:419–33. doi: 10.1371/journal.pone.0053547. [PubMed: 23300938]. [PubMed Central: PMC3534024].
  • 12. Schon C, Hoffmann NA, Ochs SM, Burgold S, Filser S, Steinbach S, et al. Long-term in vivo imaging of fibrillar tau in the retina of P301S transgenic mice. PLoS One. 2012;7(12). e53547. doi: 10.1371/journal.pone.0053547. [PubMed: 23300938]. [PubMed Central: PMC3534024].
  • 13. Zhao H, Chang R, Che H, Wang J, Yang L, Fang W, et al. Hyperphosphorylation of tau protein by calpain regulation in retina of Alzheimer's disease transgenic mouse. Neurosci Lett. 2013;551:12-6. doi: 10.1016/j.neulet.2013.06.026. [PubMed: 23810804].
  • 14. Tsai Y, Lu B, Ljubimov AV, Girman S, Ross-Cisneros FN, Sadun AA, et al. Ocular changes in TgF344-AD rat model of Alzheimer's disease. Invest Ophthalmol Vis Sci. 2014;55(1):523-34. doi: 10.1167/iovs.13-12888. [PubMed: 24398104]. [PubMed Central: PMC3907137].
  • 15. Antes R, Ezra-Elia R, Weinberger D, Solomon A, Ofri R, Michaelson DM. ApoE4 induces synaptic and ERG impairments in the retina of young targeted replacement apoE4 mice. PLoS One. 2013;8(5). e64949. doi: 10.1371/journal.pone.0064949. [PubMed: 23741431]. [PubMed Central: PMC3669199].
  • 16. Perez de Lara MJ, Pintor J. Presence and release of ATP from the retina in an Alzheimer's disease model. J Alzheimers Dis. 2015;43(1):177-81. doi: 10.3233/JAD-141005. [PubMed: 25061048].
  • 17. Pogue AI, Dua P, Hill JM, Lukiw WJ. Progressive inflammatory pathology in the retina of aluminum-fed 5xFAD transgenic mice. J Inorg Biochem. 2015;152:206-9. doi: 10.1016/j.jinorgbio.2015.07.009. [PubMed: 26213226]. [PubMed Central: PMC4681626].
  • 18. Edwards MM, Rodriguez JJ, Gutierrez-Lanza R, Yates J, Verkhratsky A, Lutty GA. Retinal macroglia changes in a triple transgenic mouse model of Alzheimer's disease. Exp Eye Res. 2014;127:252-60. doi: 10.1016/j.exer.2014.08.006. [PubMed: 25149907]. [PubMed Central: PMC4175519].
  • 19. More SS, Vince R. Hyperspectral imaging signatures detect amyloidopathy in Alzheimer's mouse retina well before onset of cognitive decline. ACS Chem Neurosci. 2015;6(2):306-15. doi: 10.1021/cn500242z. [PubMed: 25354367].
  • 20. Oliveira-Souza FG, DeRamus ML, van Groen T, Lambert AE, Bolding MS, Strang CE. Retinal changes in the Tg-SwDI mouse model of Alzheimer's disease. Neuroscience. 2017;354:43-53. doi: 10.1016/j.neuroscience.2017.04.021. [PubMed: 28450267]. [PubMed Central: PMC5495115].
  • 21. Stefanova NA, Kozhevnikova OS, Vitovtov AO, Maksimova KY, Logvinov SV, Rudnitskaya EA, et al. Senescence-accelerated OXYS rats: a model of age-related cognitive decline with relevance to abnormalities in Alzheimer disease. Cell Cycle. 2014;13(6):898-909. doi: 10.4161/cc.28255. [PubMed: 24552807]. [PubMed Central: PMC3984313].
  • 22. Kozhevnikova OS, Korbolina EE, Stefanova NA, Muraleva NA, Orlov YL, Kolosova NG. Association of AMD-like retinopathy development with an Alzheimer's disease metabolic pathway in OXYS rats. Biogerontology. 2013;14(6):753-62. doi: 10.1007/s10522-013-9439-2. [PubMed: 23959258].
  • 23. Greeve I, Kretzschmar D, Tschape JA, Beyn A, Brellinger C, Schweizer M, et al. Age-dependent neurodegeneration and Alzheimer-amyloid plaque formation in transgenic Drosophila. J Neurosci. 2004;24(16):3899-906. doi: 10.1523/JNEUROSCI.0283-04.2004. [PubMed: 15102905].
  • 24. Du LY, Chang LY, Ardiles AO, Tapia-Rojas C, Araya J, Inestrosa NC, et al. Alzheimer's Disease-Related Protein Expression in the Retina of Octodon degus. PLoS One. 2015;10(8). e0135499. doi: 10.1371/journal.pone.0135499. [PubMed: 26267479]. [PubMed Central: PMC4534194].
  • 25. Hurley MJ, Deacon RMJ, Beyer K, Ioannou E, Ibáñez A, Teeling JL, et al. The long-lived Octodon degus as a rodent drug discovery model for Alzheimer's and other age-related diseases. Pharmacol Therapeutic. 2018;188:36-44. doi: 10.1016/j.pharmthera.2018.03.001.
  • 26. Williams PA, Thirgood RA, Oliphant H, Frizzati A, Littlewood E, Votruba M, et al. Retinal ganglion cell dendritic degeneration in a mouse model of Alzheimer's disease. Neurobiol Aging. 2013;34(7):1799-806. doi: 10.1016/j.neurobiolaging.2013.01.006. [PubMed: 23465714].
  • 27. Chidlow G, Wood JP, Manavis J, Finnie J, Casson RJ. Investigations into Retinal Pathology in the Early Stages of a Mouse Model of Alzheimer's Disease. J Alzheimers Dis. 2017;56(2):655-75. doi: 10.3233/JAD-160823. [PubMed: 28035930]. [PubMed Central: PMC5271427].
  • 28. Gallagher JJ, Zhang X, Ziomek GJ, Jacobs RE, Bearer EL. Deficits in axonal transport in hippocampal-based circuitry and the visual pathway in APP knock-out animals witnessed by manganese enhanced MRI. Neuroimage. 2012;60(3):1856-66. doi: 10.1016/j.neuroimage.2012.01.132. [PubMed: 22500926]. [PubMed Central: PMC3328142].
  • 29. Phillips M, Boman E, Osterman H, Willhite D, Laska M. Olfactory and visuospatial learning and memory performance in two strains of Alzheimer's disease model mice--a longitudinal study. PLoS One. 2011;6(5). e19567. doi: 10.1371/journal.pone.0019567. [PubMed: 21573167]. [PubMed Central: PMC3088679].
  • 30. Melov S, Wolf N, Strozyk D, Doctrow SR, Bush AI. Mice transgenic for Alzheimer disease beta-amyloid develop lens cataracts that are rescued by antioxidant treatment. Free Radic Biol Med. 2005;38(2):258-61. doi: 10.1016/j.freeradbiomed.2004.10.023. [PubMed: 15607908].
  • 31. Pearson RC, Esiri MM, Hiorns RW, Wilcock GK, Powell TP. Anatomical correlates of the distribution of the pathological changes in the neocortex in Alzheimer disease. Proc Natl Acad Sci. 1985;82(13):4531-4. doi: 10.1073/pnas.82.13.4531.
  • 32. Lewis DA, Campbell MJ, Terry RD, Morrison JH. Laminar and regional distributions of neurofibrillary tangles and neuritic plaques in Alzheimer's disease: a quantitative study of visual and auditory cortices. J Neurosci. 1987;7(6):1799-808. [PubMed: 2439665].
  • 33. Ikonomovic MD, Mufson EJ, Wuu J, Bennett DA, DeKosky ST. Reduction of choline acetyltransferase activity in primary visual cortex in mild to moderate Alzheimer's disease. Arch Neurol. 2005;62(3):425-30. doi: 10.1001/archneur.62.3.425. [PubMed: 15767507].
  • 34. Grunthal E. Zur hirnpathologischen analyse der alzheimerschen krankheit. Psychiatrisch Neurologische Wochenschrift. 1928;36:401-7.
  • 35. Hof PR, Morrison JH. Quantitative analysis of a vulnerable subset of pyramidal neurons in Alzheimer's disease: II. Primary and secondary visual cortex. J Comp Neurol. 1990;301(1):55-64. doi: 10.1002/cne.903010106.
  • 36. Mendez MF, Turner J, Gilmore GC, Remler B, Tomsak RL. Balint's syndrome in Alzheimer's disease: visuospatial functions. Int J Neurosci. 1990;54(3-4):339-46. [PubMed: 2265983].
  • 37. Hof PR, Bouras C, Constantinidis J, Morrison JH. Selective disconnection of specific visual association pathways in cases of Alzheimer's disease presenting with Balint's syndrome. J Neuropathol Exp Neurol. 1990;49(2):168-84. [PubMed: 2307982].
  • 38. Pietrini P, Furey ML, Graff-Radford N, Freo U, Alexander GE, Grady CL, et al. Preferential metabolic involvement of visual cortical areas in a subtype of Alzheimer's disease: clinical implications. Am J Psychiatry. 1996;153(10):1261-8. doi: 10.1176/ajp.153.10.1261. [PubMed: 8831432].
  • 39. Nestor PJ, Caine D, Fryer TD, Clarke J, Hodges JR. The topography of metabolic deficits in posterior cortical atrophy (the visual variant of Alzheimer's disease) with FDG-PET. J Neurol Neurosurg Psychiatry. 2003;74(11):1521-9. [PubMed: 14617709]. [PubMed Central: PMC1738241].
  • 40. Leuba G, Saini K. Pathology of subcortical visual centres in relation to cortical degeneration in Alzheimer's disease. Neuropathol Appl Neurobiol. 1995;21(5):410-22. [PubMed: 8632836].
  • 41. Scinto LF, Wu CK, Firla KM, Daffner KR, Saroff D, Geula C. Focal pathology in the Edinger-Westphal nucleus explains pupillary hypersensitivity in Alzheimer's disease. Acta Neuropathol. 1999;97(6):557-64. [PubMed: 10378374].
  • 42. Rüb U, Del Tredici K, Schultz C, Büttner-Ennever JA, Braak H. The premotor region essential for rapid vertical eye movements shows early involvement in Alzheimer's disease-related cytoskeletal pathology. Vision Research. 2001;41(16):2149-56. doi: 10.1016/s0042-6989(01)00090-6.
  • 43. Rahimi J, Milenkovic I, Kovacs GG. Patterns of Tau and alpha-synuclein pathology in the visual system. J Parkinsons Dis. 2015;5(2):333-40. doi: 10.3233/JPD-140485. [PubMed: 25737267].
  • 44. Hinton DR, Sadun AA, Blanks JC, Miller CA. Optic-nerve degeneration in Alzheimer's disease. N Engl J Med. 1986;315(8):485-7. doi: 10.1056/NEJM198608213150804. [PubMed: 3736630].
  • 45. Sadun AA, Bassi CJ. Optic nerve damage in Alzheimer's disease. Ophthalmol. 1990;97(1):9-17. doi: 10.1016/s0161-6420(90)32621-0.
  • 46. Blanks JC, Hinton DR, Sadun AA, Miller CA. Retinal ganglion cell degeneration in Alzheimer's disease. Brain Res. 1989;501(2):364-72. doi: 10.1016/0006-8993(89)90653-7.
  • 47. Blanks JC, Torigoe Y, Hinton DR, Blanks RH. Retinal pathology in Alzheimer's disease. I. Ganglion cell loss in foveal/parafoveal retina. Neurobiol Aging. 1996;17(3):377-84. doi: 10.1016/0197-4580(96)00009-7.
  • 48. Blanks JC, Schmidt SY, Torigoe Y, Porrello KV, Hinton DR, Blanks RHI. Retinal pathology in Alzheimer's disease. II. Regional neuron loss and glial changes in GCL. Neurobiol Aging. 1996;17(3):385-95. doi: 10.1016/0197-4580(96)00009-7.
  • 49. Wang MY, Ross-Cisneros FN, Aggarwal D, Liang CY, Sadun AA. Receptor for advanced glycation end products is upregulated in optic neuropathy of Alzheimer's disease. Acta Neuropathol. 2009;118(3):381-9. doi: 10.1007/s00401-009-0513-4. [PubMed: 19277685]. [PubMed Central: PMC2867613].
  • 50. Goldstein LE, Muffat JA, Cherny RA, Moir RD, Ericsson MH, Huang X, et al. Cytosolic β-amyloid deposition and supranuclear cataracts in lenses from people with Alzheimer's disease. The Lancet. 2003;361(9365):1258-65. doi: 10.1016/s0140-6736(03)12981-9.
  • 51. Moncaster JA, Pineda R, Moir RD, Lu S, Burton MA, Ghosh JG, et al. Alzheimer's disease amyloid-beta links lens and brain pathology in Down syndrome. PLoS One. 2010;5(5). e10659. doi: 10.1371/journal.pone.0010659. [PubMed: 20502642]. [PubMed Central: PMC2873949].
  • 52. La Morgia C, Ross-Cisneros FN, Koronyo Y, Hannibal J, Gallassi R, Cantalupo G, et al. Melanopsin retinal ganglion cell loss in Alzheimer disease. Ann Neurol. 2016;79(1):90-109. doi: 10.1002/ana.24548. [PubMed: 26505992]. [PubMed Central: PMC4737313].
  • 53. Davies DC, McCoubrie P, McDonald B, Jobst KA. Myelinated axon number in the optic nerve is unaffected by Alzheimer's disease. Br J Ophthalmol. 1995;79(6):596-600. [PubMed: 7542917]. [PubMed Central: PMC505173].
  • 54. Ho CY, Troncoso JC, Knox D, Stark W, Eberhart CG. Beta-amyloid, phospho-tau and alpha-synuclein deposits similar to those in the brain are not identified in the eyes of Alzheimer's and Parkinson's disease patients. Brain Pathol. 2014;24(1):25-32. doi: 10.1111/bpa.12070. [PubMed: 23714377]. [PubMed Central: PMC3976129].
  • 55. Williams EA, McGuone D, Frosch MP, Hyman BT, Laver N, Stemmer-Rachamimov A. Absence of Alzheimer Disease Neuropathologic Changes in Eyes of Subjects With Alzheimer Disease. J Neuropathol Exp Neurol. 2017;76(5):376-83. doi: 10.1093/jnen/nlx020. [PubMed: 28379416].
  • 56. Loffler KU, Edward DP, Tso MO. Immunoreactivity against tau, amyloid precursor protein, and beta-amyloid in the human retina. Invest Ophthalmol Vis Sci. 1995;36(1):24-31. [PubMed: 7822152].
  • 57. Curcio CA, Drucker DN. Retinal ganglion cells in Alzheimer's disease and aging. Ann Neurol. 1993;33(3):248-57. doi: 10.1002/ana.410330305. [PubMed: 8498808].
  • 58. Leger F, Fernagut PO, Canron MH, Leoni S, Vital C, Tison F, et al. Protein aggregation in the aging retina. J Neuropathol Exp Neurol. 2011;70(1):63-8. doi: 10.1097/NEN.0b013e31820376cc. [PubMed: 21157377].
  • 59. Johnson LV, Leitner WP, Rivest AJ, Staples MK, Radeke MJ, Anderson DH. The Alzheimer's A beta -peptide is deposited at sites of complement activation in pathologic deposits associated with aging and age-related macular degeneration. Proc Natl Acad Sci U S A. 2002;99(18):11830-5. doi: 10.1073/pnas.192203399. [PubMed: 12189211]. [PubMed Central: PMC129354].
  • 60. Luibl V, Isas JM, Kayed R, Glabe CG, Langen R, Chen J. Drusen deposits associated with aging and age-related macular degeneration contain nonfibrillar amyloid oligomers. J Clin Invest. 2006;116(2):378-85. doi: 10.1172/JCI25843. [PubMed: 16453022]. [PubMed Central: PMC1359048].
  • 61. Yoneda S, Hara H, Hirata A, Fukushima M, Inomata Y, Tanihara H. Vitreous fluid levels of beta-amyloid((1-42)) and tau in patients with retinal diseases. Jpn J Ophthalmol. 2005;49(2):106-8. doi: 10.1007/s10384-004-0156-x. [PubMed: 15838725].
  • 62. Baird PN, Richardson AJ, Robman LD, Dimitrov PN, Tikellis G, McCarty CA, et al. Apolipoprotein (APOE) gene is associated with progression of age-related macular degeneration (AMD). Hum Mutat. 2006;27(4):337-42. doi: 10.1002/humu.20288. [PubMed: 16453339].
  • 63. Westerman MA, Cooper-Blacketer D, Mariash A, Kotilinek L, Kawarabayashi T, Younkin LH, et al. The relationship between Abeta and memory in the Tg2576 mouse model of Alzheimer's disease. J Neurosci. 2002;22(5):1858-67. [PubMed: 11880515].
  • 64. Scattoni ML, Gasparini L, Alleva E, Goedert M, Calamandrei G, Spillantini MG. Early behavioural markers of disease in P301S tau transgenic mice. Behav Brain Res. 2010;208(1):250-7. doi: 10.1016/j.bbr.2009.12.002. [PubMed: 20004218].
  • 65. Brown RE, Wong AA. The influence of visual ability on learning and memory performance in 13 strains of mice. Learn Mem. 2007;14(3):134-44. doi: 10.1101/lm.473907. [PubMed: 17351136]. [PubMed Central: PMC1838554].
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .
Readers' Comments